Literature DB >> 17666557

COPD prevalence in a random population survey: a matter of definition.

P Shirtcliffe1, M Weatherall, S Marsh, J Travers, A Hansell, A McNaughton, S Aldington, H Muellerova, R Beasley.   

Abstract

A recent American Thoracic Society and European Respiratory Society joint Task Force report recommends using a lower limit of normal (LLN) of forced expiratory volume in one second/forced vital capacity as opposed to a fixed ratio of <0.7 to diagnose airflow obstruction, in order to reduce false positive diagnoses of chronic obstructive pulmonary disease (COPD) as defined by the Global Initiative for Obstructive Lung Disease (GOLD). To date, there is no reliable spirometry-based prevalence data for COPD in New Zealand and the effect of different definitions of airflow obstruction based on post-bronchodilator spirometry is not known. Detailed written questionnaires, full pulmonary function tests (including pre- and post-bronchodilator flow-volume loops) and atopy testing were completed in 749 subjects recruited from a random population sample. The GOLD-defined, age-adjusted prevalence (95% confidence interval) for adults aged >or=40 yrs was 14.2 (11.0-17.0)% compared with an LLN-defined, age-adjusted, post-bronchodilator prevalence in the same group of 9.0 (6.7-11.3)%. The prevalence of chronic obstructive pulmonary disease varied markedly depending on the definition used. Further research using longitudinal rather than cross-sectional data will help decide the preferred approach in chronic obstructive pulmonary disease prevalence surveys.

Entities:  

Mesh:

Year:  2007        PMID: 17666557      PMCID: PMC2516341          DOI: 10.1183/09031936.00157906

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  27 in total

1.  Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994.

Authors:  D M Mannino; R C Gagnon; T L Petty; E Lydick
Journal:  Arch Intern Med       Date:  2000-06-12

Review 2.  Epidemiology and costs of chronic obstructive pulmonary disease.

Authors:  K R Chapman; D M Mannino; J B Soriano; P A Vermeire; A S Buist; M J Thun; C Connell; A Jemal; T A Lee; M Miravitlles; S Aldington; R Beasley
Journal:  Eur Respir J       Date:  2006-01       Impact factor: 16.671

3.  FEV1/FVC ratio of 70% misclassifies patients with obstruction at the extremes of age.

Authors:  Scott D Roberts; Mark O Farber; Kenneth S Knox; Gary S Phillips; Nitin Y Bhatt; John G Mastronarde; Karen L Wood
Journal:  Chest       Date:  2006-07       Impact factor: 9.410

4.  Chronic obstructive pulmonary disease: current burden and future projections.

Authors:  A D Lopez; K Shibuya; C Rao; C D Mathers; A L Hansell; L S Held; V Schmid; S Buist
Journal:  Eur Respir J       Date:  2006-02       Impact factor: 16.671

5.  Complete reference ranges for pulmonary function tests from a single New Zealand population.

Authors:  Suzanne Marsh; Sarah Aldington; Mathew Williams; Mark Weatherall; Philippa Shirtcliffe; Amanda McNaughton; Alison Pritchard; Richard Beasley
Journal:  N Z Med J       Date:  2006-10-27

6.  Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study.

Authors:  Ana Maria B Menezes; Rogelio Perez-Padilla; José Roberto B Jardim; Adriana Muiño; Maria Victorina Lopez; Gonzalo Valdivia; Maria Montes de Oca; Carlos Talamo; Pedro C Hallal; Cesar G Victora
Journal:  Lancet       Date:  2005-11-26       Impact factor: 79.321

7.  Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function?

Authors:  David M Mannino; A Sonia Buist; William M Vollmer
Journal:  Thorax       Date:  2006-11-07       Impact factor: 9.139

Review 8.  Global burden of COPD: systematic review and meta-analysis.

Authors:  R J Halbert; J L Natoli; A Gano; E Badamgarav; A S Buist; D M Mannino
Journal:  Eur Respir J       Date:  2006-04-12       Impact factor: 16.671

9.  Post-bronchodilator spirometry reference values in adults and implications for disease management.

Authors:  Ane Johannessen; Sverre Lehmann; Ernst R Omenaas; Geir Egil Eide; Per S Bakke; Amund Gulsvik
Journal:  Am J Respir Crit Care Med       Date:  2006-03-23       Impact factor: 21.405

10.  Physiological associations of computerized tomography lung density: a factor analysis.

Authors:  Suzanne Marsh; Sarah Aldington; Mathew V Williams; Michael Nowitz; Andrew Kingzett-Taylor; Mark Weatherall; Phillipa Shirtcliffe; Alison Pritchard; Richard Beasley
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006
View more
  38 in total

1.  Diagnosis of airway obstruction or restrictive spirometric patterns by multiclass support vector machines.

Authors:  Deniz Sahin; Elif Derya Ubeyli; Gul Ilbay; Murat Sahin; Alisan Burak Yasar
Journal:  J Med Syst       Date:  2009-05-12       Impact factor: 4.460

2.  Early detection of COPD combined with individualized counselling for smoking cessation: a two-year prospective study.

Authors:  Tuula Toljamo; Marjo Kaukonen; Pentti Nieminen; Vuokko L Kinnula
Journal:  Scand J Prim Health Care       Date:  2010-03       Impact factor: 2.581

3.  Genetic ancestry in lung-function predictions.

Authors:  Rajesh Kumar; Max A Seibold; Melinda C Aldrich; L Keoki Williams; Alex P Reiner; Laura Colangelo; Joshua Galanter; Christopher Gignoux; Donglei Hu; Saunak Sen; Shweta Choudhry; Edward L Peterson; Jose Rodriguez-Santana; William Rodriguez-Cintron; Michael A Nalls; Tennille S Leak; Ellen O'Meara; Bernd Meibohm; Stephen B Kritchevsky; Rongling Li; Tamara B Harris; Deborah A Nickerson; Myriam Fornage; Paul Enright; Elad Ziv; Lewis J Smith; Kiang Liu; Esteban González Burchard
Journal:  N Engl J Med       Date:  2010-07-07       Impact factor: 91.245

4.  ARTP statement on pulmonary function testing 2020.

Authors:  Karl Peter Sylvester; Nigel Clayton; Ian Cliff; Michael Hepple; Adrian Kendrick; Jane Kirkby; Martin Miller; Alan Moore; Gerrard Francis Rafferty; Liam O'Reilly; Joanna Shakespeare; Laurie Smith; Trefor Watts; Martyn Bucknall; Keith Butterfield
Journal:  BMJ Open Respir Res       Date:  2020-07

5.  Understanding the true burden of COPD: the epidemiological challenges.

Authors:  Sundeep S Salvi; Roslina Manap; Richard Beasley
Journal:  Prim Care Respir J       Date:  2012-09

Review 6.  Should mild COPD be treated? Evidence for early pharmacological intervention.

Authors:  Amany F Elbehairy; Katherine A Webb; J Alberto Neder; J Alberto Neder; Denis E O'Donnell
Journal:  Drugs       Date:  2013-12       Impact factor: 9.546

Review 7.  Asthma and chronic obstructive pulmonary disease.

Authors:  Stefano Guerra
Journal:  Curr Opin Allergy Clin Immunol       Date:  2009-10

8.  Relationship of serum gamma-glutamyltransferase levels with pulmonary function and chronic obstructive pulmonary disease.

Authors:  Hyun-Woo Kim; Seock-Hwan Lee; Duk-Hee Lee
Journal:  Lung       Date:  2014-07-11       Impact factor: 2.584

9.  Proportional classifications of COPD phenotypes.

Authors:  S E Marsh; J Travers; M Weatherall; M V Williams; S Aldington; P M Shirtcliffe; A L Hansell; M R Nowitz; A A McNaughton; J B Soriano; R W Beasley
Journal:  Thorax       Date:  2008-09       Impact factor: 9.139

Review 10.  What defines abnormal lung function in older adults with chronic obstructive pulmonary disease?

Authors:  Nitin Y Bhatt; Karen L Wood
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.